Survival outcomes. (A) Outcomes for all children treated at Great Ormond Street Hospital with genome-edited allo-CAR19 T cells. Periods of allo-CAR19 intervention (blue), complete remission (orange), or relapse (gray) are illustrated after 2 to 10 years of follow-up. (B) EFS and OS with 40% of subjects in long-term remission above 2 years. EFS, event-free survival; OS, overall survival; P, trial UCART19 (P); S, specials license UCAR19; TT, trial TT52CAR19.
Figure 1.

Survival outcomes. (A) Outcomes for all children treated at Great Ormond Street Hospital with genome-edited allo-CAR19 T cells. Periods of allo-CAR19 intervention (blue), complete remission (orange), or relapse (gray) are illustrated after 2 to 10 years of follow-up. (B) EFS and OS with 40% of subjects in long-term remission above 2 years. EFS, event-free survival; OS, overall survival; P, trial UCART19 (P); S, specials license UCAR19; TT, trial TT52CAR19.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal